Of particular interest were pancreatic cancer (PAAD) and clear cell renal cell carcinoma (ccRCC), which also seem like attractive targets for P-selectin-targeted therapies (Figure 3—figure supplement 2). This evidence concerns the gene SELP and pancreatic neoplasm.